News | January 21, 2026
Neurizon locks in global trademark protection across key pharma markets
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The trademark rights for these brands will be transferred to Lupin by March next year.
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Subscribe To Our Newsletter & Stay Updated
